Vimarsana
Biggest News Aggregation in the World

Annie Cheng News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Annie Cheng. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Annie Cheng Today - Breaking & Trending Today

PR Awards Asia-Pacific 2024: Entries now open | News - Vimarsana News

PR Awards Asia-Pacific 2024: Entries now open | News

Now in its 23rd year, PR Awards Asia-Pacific shines a spotlight on the region’s most successful campaigns, individuals, and companies in the communications industry.

HUTCHMED Highlights Presentation of Results from the Phase - Vimarsana News

HUTCHMED Highlights Presentation of Results from the Phase

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today...

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer - Vimarsana News

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 -- HUTCHMED Limited ; class='js-l-obf link link--blue'

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China - Vimarsana News

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — —...

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 - Vimarsana News

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01

— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with...